WHO: Estimated Incidence of Curable STIs 376.4 Million in 2016
THURSDAY, June 6, 2019 -- The estimated incidence of urogenital infections with chlamydia, gonorrhea, trichomoniasis, and syphilis was 376.4 million in 15- to 49-year-old men and women in 2016, according to research published online June 6 in the Bulletin of the World Health Organization.
Jane Rowley, Ph.D., from the World Health Organization in Geneva, and colleagues generated estimates of the prevalence and incidence of urogenital infection with chlamydia, gonorrhea, trichomoniasis, and syphilis in women and men aged 15 to 49 years in 2016. Estimates were generated from 130 eligible studies conducted between 2009 and 2016 reporting on chlamydia, gonorrhea, and/or trichomoniasis and from 978 data points from the Spectrum-STI database for syphilis during the same period.
The researchers found that the global prevalence estimates in 2016 were 3.8, 0.9, 5.3, and 0.5 percent for chlamydia, gonorrhea, trichomoniasis, and syphilis, respectively, for women. The corresponding prevalence estimates were 2.7, 0.7, 0.6, and 0.5 percent, respectively, for men. The total estimated incident cases were 376.4 million: 127.2, 86.9, 156.0, and 6.3 million cases of chlamydia, gonorrhea, trichomoniasis, and syphilis, respectively.
"We're seeing a concerning lack of progress in stopping the spread of sexually transmitted infections worldwide," Peter Salama, M.D., executive director for Universal Health Coverage and the Life-Course at the WHO, said in a statement. "This is a wake-up call for a concerted effort to ensure everyone, everywhere can access the services they need to prevent and treat these debilitating diseases."
© 2020 HealthDay. All rights reserved.
Posted: June 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.